Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Perez-Gracia, J.L. (Jose Luis) | - |
dc.creator | Fernandez-Sanmamed, M. (Miguel) | - |
dc.creator | Melero, I. (Ignacio) | - |
dc.date.accessioned | 2023-02-14T09:18:15Z | - |
dc.date.available | 2023-02-14T09:18:15Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Perez-Gracia, J.L. (Jose Luis); Fernandez-Sanmamed, M. (Miguel); Melero, I. (Ignacio). "Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?". Translational lung cancer research. 7 (Supl. 4), 2018, 356 - 357 | es |
dc.identifier.issn | 2218-6751 | - |
dc.identifier.uri | https://hdl.handle.net/10171/65451 | - |
dc.description.abstract | Recently, Forde et al. reported in the New England Journal of Medicine a pilot study in which two neoadjuvant doses of the PD-1 inhibitor nivolumab were administered in a preoperative fashion to 21 patients with untreated, surgically resectable early (stage I–IIIA) non-small cell lung cancer (NSCLC) (1). Surgery was performed 4 weeks after the first dose of nivolumab. In addition to an acceptable toxicity profile, which did not cause delays in surgery, nivolumab induced a major pathological response in 9 of 20 resected tumors (45%). Pathological responses were observed in patients presenting PD-L1 positive and negative tumors and, interestingly, they correlated with pretreatment tumor mutational burden. The authors found that the number of T-cell clones observed in the tumor and peripheral blood increased following nivolumab in eight of nine patients. Remarkably, the authors described one patient presenting a complete response in which neoantigen-specific T-cell clones from the primary tumor rapidly expanded in peripheral blood following treatment. Moreover, some of these clones were not detected before treatment with nivolumab, thus suggesting that PD-1 blockade induced their expansion. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | AME Publishing | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | PD-1 inhibitor nivolumab | es_ES |
dc.subject | Cell lung cancer | es_ES |
dc.title | Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better? | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) | es_ES |
dc.identifier.doi | 10.21037/tlcr.2018.10.12 | - |
dadun.citation.endingPage | 357 | es_ES |
dadun.citation.number | Supl. 4 | es_ES |
dadun.citation.publicationName | Translational lung cancer research | es_ES |
dadun.citation.startingPage | 356 | es_ES |
dadun.citation.volume | 7 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.